Dunja Urosev

Dunja Urosev is a highly experienced scientist currently serving as Principal Scientist and Group Lead at Zymeworks Inc., where a successful IgG-like bispecific antibody platform was developed and licensed to multiple pharmaceutical companies. This role includes leading stable cell line development and overseeing engineering projects to enhance antibody manufacturability. Prior experience includes a Postdoctoral Fellowship at Universitat Autonoma de Barcelona, focusing on crystallization and protein structure resolution for vaccine research. Dunja holds MSc and PhD degrees in Biochemistry/Biophysics from The University of British Columbia and BSc and MSc degrees in Biochemistry from Lomonosov Moscow State University.